Diamyd Medical is approaching a critical time. The Swedish company’s vaccine aimed at slowing the progress of type 1 diabetes begins reporting phase III trial results in late spring, which will help determine whether partner Johnson & Johnson wants to follow through on its option to develop and commericialise the therapy.Positive results will likely result in a milestone payment to Diamyd and persuade J&J to pick up the remaining development costs for the eponymous immunotherapy product (Diamyd continues winning streak with J&J deal, June 23, 2010). Expectations for the vaccine have been building since the company reported promising follow-up data on its phase II trials 18 months ago, suggesting the vaccine may represent a significant breakthrough in the treatment of the autoimmune form of diabetes.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: email@example.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
Terms & Conditions